论文部分内容阅读
目的:探讨门冬氨酸鸟氨酸治疗肝性脑病的临床效果及其对相关生化指标的影响。方法:选取武警部队海警总队医院2018年8月至2019年8月诊治的肝性脑病患者100例，采用随机数字表法分为对照组、观察组各50例，对照组采用常规综合治疗，观察组在常规综合治疗基础上加用门冬氨酸鸟氨酸治疗，两组疗程均为1周。观察两组肝功能指标、血氨水平变化及临床效果。结果:治疗后，观察组丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、血清总胆红素（TBIL）、血氨（NHn 3）分别为（61.84±11.34）IU/L、（47.67±12.37）IU/L、（37.96±5.56）μmol/L、（54.85±12.73）μmol/L，均显著低于对照组的（81.48±10.63）IU/L、（64.30±13.52）IU/L、（50.74±6.73）μmol/L、（68.56±12.63）μmol/L（n t=8.935、6.417、10.352、5.406，均n P<0.05）；观察组肝性脑病评分为（0.77± 0.06）分，显著低于对照组的（1.68±0.10）分（n t=55.177，n P<0.05）；观察组总有效率为90.0%（45/50），高于对照组的74.0%（36/50）（χn 2=5.263，n P<0.05）；观察组数字连接试验（NCT）时间为（45.85±4.27）s，短于对照组的（59.58±5.63）s，数字符号试验（DST）、格拉斯哥预后评分（GOS评分）分别为（56.25±9.76）分、（4.76±0.63）分，均高于对照组的（41.53±9.62）分、（3.31±0.25）分（n t=13.740、7.595、15.127，均n P<0.05）。n 结论:门冬氨酸鸟氨酸可有效改善肝性脑病患者肝功能，降低NHn 3水平，提高临床疗效，改善患者认知功能和预后。n “,”Objective:To investigate the clinical effect of ornithine aspartate in the treatment of hepatic encephalopathy and its influence on related biochemical indexes.Methods:A total of 100 patients with hepatic encephalopathy who received treatment in the Marine Police Corps Hospital of the Chinese People's Armed Police Force from August 2018 to August 2019 were included in this study. They were randomly assigned to receive conventional comprehensive treatment (control group, n n = 50) or conventional comprehensive treatment combined with ornithine aspartate treatment (observation group, n n = 50). Both groups of patients received 1 week of treatment. Liver function index, blood ammonia level, and clinical therapeutic effect were determined in both groups.n Results:After treatment,alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL) and ammonia (NHn 3) levels in the observation group were (61.84 ± 11.34) IU/L,(47.67 ± 12.37) IU/L, (37.96 ± 5.56) μmol/L and (54.85 ± 12.73) μmol/L, respectively, which were significantly lower than (81.48 ± 10.63) IU/L, (64.30 ± 13.52) IU/L, (50.74 ± 6.73) μmol/L, and (68.56 ± 12.63) μmol/L respectively in the control group (n t = 8.935, 6.417, 10.352, 5.406, all n P < 0.05). The score of hepatic encephalopathy in the observation group was significantly lower than that in the control group [(0.77 ± 0.06) points n vs. (1.68 ± 0.10) points, n t = 55.177, n P < 0.05]. Total effective rate in the observation group was significantly higher than that in the control group [90.0% (45/50) n vs. 74.0% (36/50), χn 2= 5.263, n P < 0.05]. The time of number connection test in the observation group was significantly shorter than that in the control group [(45.85 ± 4.27) s n vs. (59.58 ± 5.63) s, n t =13.740, n P < 0.05]. Digit symbol test score and Glasgow outcome scale score in the observation group were (56.25 ± 9.76) points and (4.76 ± 0.63) points, respectively, which were significantly higher than (41.53 ± 9.62) points and n (3.31 ± 0.25) points respectively in the control group (n t = 7.595, 15.127, both n P < 0.05).n Conclusion:Ornithine aspartate can effectively improve the liver function of patients with hepatic encephalopathy, reduce the level of NH3, improve cognitive function and prognosis, and thereby improve clinical efficacy.